Q-MED's interim report for the first nine months of 1999

Q-MED's interim report for the first nine months of 1999 Net sales increased 71% to SEK 99 (58) million. Income after financial items amounted to SEK 13.3 (13.6) million New product - Deflux 3 - approved for the treatment of stress urinary incontinence Revenues and income Q-Med reports continued strong growth during the period. Sales amounted to SEK 98.7 (57.7) million, which is an increase of 71 per cent compared with the corresponding period the preceding year. Operating income was SEK 14.6 (14.2) million, which resulted in a lower profit margin than the previous year. This was due to heavy investment in research and product development and to market- related costs for the building up of the company's own sales organisation in priority markets. [REMOVED GRAPHICS] ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/10/22/19991103BIT00250/bit0001.doc http://www.bit.se/bitonline/1999/10/22/19991103BIT00250/bit0002.pdf